protein therapeutic News
-
Lumen Bioscience Partners with Leading Animal Health Company to Develop Oral Biologic Drugs and Reduce Antibiotic Use on Farms
Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced a research collaboration with a top-three animal health company to develop orally delivered biologic drugs to reduce the use of antibiotics in animal husbandry. The collaboration’s initial focus is on development of therapeutic proteins against ...
-
Araris Biotech AG to Present at Informa Connect’s Next Generation Protein Therapeutics Summit
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the company’s chief executive officer, Philipp Spycher, Ph.D., will be a speaker at the Next Generation Protein Therapeutics Summit hosted by Informa Connect. The presentation will highlight Araris’ proprietary linker technology, which enables the conjugation of ...
-
Orion Biotechnology Successfully Completes Phase I Clinical Study of 0B-002H Topical Gel for HIV Prevention
Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today announced successful completion of participant follow-up in their Phase 1 study of OB-002H which is an investigational candidate microbicide. The Phase 1 study was a first-in-man trial designed to evaluate the safety, acceptability, and pharmacokinetic ...
-
Creative BioMart Updated Its Protein Engineering Rational Design Services
Creative BioMart, a leading customer-centric biotechnology company that is currently developing the potential based on protein engineering technology, recently updated its protein engineering rational design services to help scientists solve problems encountered in their projects. The knowledge of protein structure-function relationships is improved by proteins created through rational design, ...
-
GC Pharma Taps Small Molecule AI Expert Atomwise to Expand Hemophilia Franchise
Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today a partnership with GC Pharma (KRX: 006280), a South Korean biopharmaceutical company formerly known as Green Cross Corporation, to discover and develop novel hemophilia therapies. GC Pharma is a pioneer in vaccines and protein therapeutics and has long been dedicated to research and ...
-
Lumen Bioscience Announces Publication in NPJ Vaccines of Preclinical Data Demonstrating Needle Free, Spirulina-produced Vaccination Offering Protection Against Malaria
Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced the publication of data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria. The research, conducted in collaboration with the University of Washington, was published in the peer-reviewed journal, Nature Partner ...
-
Lumen Bioscience Announces Publication in Nature Biotechnology Detailing Spirulina-Based Platform for Ultra-Large-Scale Production of Therapeutic Proteins
Researchers describe rapid, low-cost drug development approach Paper also reports preclinical and early clinical data for LMN-101 A common food source has been converted into a biomanufacturing platform that offers a way to rapidly produce mass quantities of biologic drugs for common diseases that currently lack effective treatments. Researchers at Lumen Bioscience report in Nature ...
-
Orion presented the Results of our Successful Phase 1 Clinical Trial at the HIV Research for Prevention Conference
Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today announced that they will be presenting the results of their Phase 1 study of OB-002H at the HIVR4P virtual meeting (https://www.hivr4p.org/). The OB-002H-101 Phase 1 study was a first-in-man trial designed to evaluate the safety, acceptability, and ...
-
Orion Biotechnology Receives Funding to Test OB-002 for Treatment of COVID-19
Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today announced that it is receiving advisory services and conditional funding from the National Research Council Industrial Research Assistance Program (NRC IRAP), to support the development of Orion’s lead compound, OB-002, a promising treatment for ...
-
Bayer and Berkeley Lights announce a multi-year agreement aimed at revolutionizing the discovery of next-generation traits
Bayer announced a multi-year agreement with Berkeley Lights, Inc. (Nasdaq: BLI) a leader in the functional characterization of live biology, to develop and perform high-throughput functional screening workflows aimed at accelerating and expanding the discovery of novel traits. Terms of the agreement were not disclosed. Berkeley Lights will leverage its platform to screen individual variants of ...
-
Eyevensys Named to French Tech 120 Program
Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, today announced it has been accepted into the French Tech 120 program for 2021. This government-backed program, run by La French Tech, offers support for 120 French startups considered late-stage and in a hypergrowth phase. Participating companies benefit from a variety ...
By Eyevensys
-
Eyevensys to present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases today announced that the company will be presenting preclinical data on its two lead candidates for geographic atrophy (GA) and wet AMD at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting. The conference will be held May 1-4, ...
By Eyevensys
-
Lumen Bioscience Announces Clinical Advancement of LMN-201 for C. difficile Infection
FDA clearance of investigational new drug (IND) application Initiation of multisite Phase 2 study in spring 2022 Phase 1 pharmacokinetic study completed Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced clinical development progress for LMN-201, an investigational orally delivered cocktail to treat and prevent C. ...
-
Eyevensys Presents Initial Data from Phase I/II, Non-Viral Gene Therapy for Ocular Diseases
Eyevensys this week presented results from part 1 of its phase I/II study for non-infectious uveitis (NIU) at the Ophthalmology Innovation Summit’s (OIS) 11th Annual OIS@AAO conference on October 10, 2019 in San Francisco. Dr. Ronald R. Buggage, MD, Chief Medical Officer of Eyevensys, discussed the novel technology during the Gene & Cell Therapy Spotlight session. The company’s ...
By Eyevensys
-
Feldan therapeutics appoints Dr Robert J. Wills to board of directors
Feldan Therapeutics, a biotechnology company focusing on the development of therapeutics based on its intracellular delivery technology, today announced the appointment of Dr. Robert J. Wills to its Board of Directors. "We are honored to welcome Dr. Robert J. Wills to Feldan’s Board of Directors,” said François-Thomas Michaud, Co-founder and Chief Executive Officer of Feldan. ...
-
Feldan therapeutics appoints Dr Robert J. Wills to board of directors
Feldan Therapeutics, a biotechnology company focusing on the development of therapeutics based on its intracellular delivery technology, today announced the appointment of Dr. Robert J. Wills to its Board of Directors. "We are honored to welcome Dr. Robert J. Wills to Feldan’s Board of Directors,” said François-Thomas Michaud, Co-founder and Chief Executive Officer of Feldan. ...
-
Aurealis Therapeutics Receives Clinical Trial Application Approval for AUP-16 Diabetic Foot Ulcer Patient Trial
Aurealis Therapeutics, a private biopharmaceutical company developing AUP-16, the three-in-one combination biologic drug for chronic non-healing wounds and regenerative diseases, announced today clinical trial application (CTA) approval of the AUP-16 phase 1 diabetic foot ulcer (DFU) patient trial by the German Health Authority Paul-Ehrlich-Institute. The company plans to enroll the first patient ...
-
Feldan therapeutics announces a publication in nature communications
In an article published in Nature Communications, entitled "Engineered Amphiphilic Peptides Enable Delivery of Proteins and CRISPR Associated Nucleases to Airway Epithelia” Dr. David Guay, Research Director of Feldan Therapeutics, and collaborator Dr. Paul McCray, from the University of Iowa Carver College of Medicine, demonstrate that Feldan’s engineered amphiphilic peptides (Feldan ...
-
T3 Pharma raises 25M CHF to advance bacterial cancer therapy through clinic
T3 Pharmaceuticals AG (“T3 Pharma”), a Swiss biotech advancing immuno-oncology with its bacteria-based protein delivery platform, today announced the closing of its third financing round, raising over 25M CHF. The financing was co-led by existing investors, including the Boehringer Ingelheim Venture Fund (BIVF), Reference Capital SA, Wille Finance AG and private investors, who all ...
-
ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases
ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases The companies agree a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vgAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases ViGeneron GmbH, a next-generation gene therapy company, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you